Beta-thalassemia intermedia
MONDO:0016487Beta-thalassemia (BT) intermedia is a form of BT characterized by mild to moderate anemia which does not or only occasionally requires transfusion.
34 clinical trials for this condition and its sub-types, 9 tagged with Beta-thalassemia intermedia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for thalassemia: drug trial targets anemia without transfusions
Disease control Not yet recruitingThis study tests a new drug called SNH-119014 in 30 adults with a type of thalassemia that does not require regular blood transfusions. The goal is to see if the drug is safe and helps improve anemia. Participants will be monitored for side effects and how their body responds to …
Phase 2 • Sponsor: ScinnoHub Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Smartwatch signals may flag anemia, no needle needed
Diagnosis Not yet recruitingAnemia often goes unnoticed because diagnosis requires a blood draw. This study tests whether a wrist-worn smartwatch can identify people likely to have anemia by tracking blood flow, heart rate, oxygen, and movement. About 400 adults, with and without anemia, will wear the watch…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Could a painless light sensor replace the needle for anemia screening?
Diagnosis Not yet recruitingThis study tests whether a non-invasive device that uses light to measure hemoglobin through the skin can accurately detect anemia. Researchers will compare its readings with standard blood tests in 150 adults in Jakarta. If the device proves reliable, it could offer a quick, pai…
Sponsor: Tarumanagara University • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
What does thalassemia really cost children and families?
Knowledge-focused Not yet recruitingThis study measures the clinical, economic, and psychosocial burden of thalassemia in children and adolescents in Sohag, Egypt. Researchers will track hospital visits, blood transfusions, and complications, and estimate direct medical costs plus indirect costs like missed school …
Sponsor: Randa Elham Hamam • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Greek study to measure daily life impact of iron overload drug
Knowledge-focused Not yet recruitingThis study looks at how thalassemia patients in Greece feel day-to-day while taking a standard iron-removing medicine called deferasirox. Researchers will survey 150 adults to measure their physical and mental well-being. The goal is to understand real-world quality of life, not …
Sponsor: Elpen Pharmaceutical Co. Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC